| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |